


Setrobuvir

Chemical Properties

| | |
|-------------------|---|
| CAS No. : | 1071517-39-9 |
| Formula: | C ₂₅ H ₂₅ FN ₄ O ₆ S ₂ |
| Molecular Weight: | 560.62 |
| Storage: | Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA. |



Biological Description

| | |
|----------------------------|--|
| Description | Setrobuvir (ANA-598) is an orally active non-nucleoside HCV NS5B polymerase inhibitor with inhibitory effects on de novo RNA synthesis and primer extension with IC ₅₀ s between 4 and 5 nM. setrobuvir shows good binding affinity for SARS-CoV-2 RdRp and induces inhibition of RdRp. |
| Targets(IC ₅₀) | HCV Protease,DNA/RNA Synthesis,SARS-CoV |
| In vivo | Setrobuvir (200, 400, and 800 mg) BID were -2.1, -2.2, and -2.9 log ₁₀ IU/mL, respectively (vs ≤0.1 log ₁₀ IU/mL with placebo).[3] |

Solubility Information

| | |
|------------|---|
| Solubility | DMSO: 252.5 mg/mL (450.39 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble) |
|------------|---|

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|-----------|-----------|------------|
| 1 mM | 1.7837 mL | 8.9187 mL | 17.8374 mL |
| 5 mM | 0.3567 mL | 1.7837 mL | 3.5675 mL |
| 10 mM | 0.1784 mL | 0.8919 mL | 1.7837 mL |
| 50 mM | 0.0357 mL | 0.1784 mL | 0.3567 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Yi G, et al. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir. *Antimicrob Agents Chemother.* 2012 ; 56(2):830-837.

Elfiky AA. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective. *J Biomol Struct Dyn.* 2021 ; 39(9):3204-3212. doi:10.1080/07391102.2020.1761882

Mallalieu NL, et al. Pharmacokinetics and pharmacodynamics of setrobuvir, an orally administered hepatitis C virus non-nucleoside analogue inhibitor. *Clin Ther.* 2014 ; 36(12):2047-2063.

Eltahla AA, et al. Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders. *Antimicrob Agents Chemother.* 2014 ; 58(12):7215-7224.

De Clercq E. Current race in the development of DAAs (direct-acting antivirals) against HCV. *Biochem Pharmacol.* 2014 ; 89(4):441-452.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481